Primary Hypercholesterolemia — Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)
Citation(s)
A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of Extended-release (ER) Niacin/Laropiprant in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia.